BM32
Unassigned
New Medicines
Hayfever, confirmed allergy to grass pollen extract with moderate to severe symptoms
Information
Vaccine
Biomay
Not Known
Development and Regulatory status
Phase II Clinical Trials
Phase II Clinical Trials
Unknown
Category
Grass pollen allergy vaccine based on recombinant peptide carrier proteins which are constructed from the immunogenic material.
Allergy to grass pollen is common and affects around 2 of every 10 people in the UK. A small minority of these pts suffer with severe symptoms of allergy [1].
Hayfever, confirmed allergy to grass pollen extract with moderate to severe symptoms
Subcutaneous injection